Astrazeneca Dividends - AZN

Astrazeneca Dividends - AZN

Best deals to access real time data!
Silver
Monthly Subscription
for only
£17.37
Level 2 Basic
Monthly Subscription
for only
£62.08
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Astrazeneca Plc AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  -49.00 -0.72% 6,772.00 6,860.00 6,763.00 6,821.00 6,821.00 16:35:11
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Astrazeneca AZN Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
25/07/2019InterimUSX9031/12/201731/12/201808/08/201909/08/201909/09/20190
14/02/2019FinalUSX19031/12/201731/12/201828/02/201901/03/201927/03/2019280
26/07/2018InterimUSX9031/12/201731/12/201809/08/201810/08/201810/09/20180
02/02/2018FinalUSX19031/12/201631/12/201715/02/201816/02/201819/03/2018280
27/07/2017InterimUSX9031/12/201631/12/201710/08/201711/08/201711/09/20170
02/02/2017FinalUSX19031/12/201531/12/201616/02/201717/02/201720/03/2017280
28/07/2016InterimUSX9031/12/201531/12/201611/08/201612/08/201612/09/20160
04/02/2016FinalUSX19031/12/201431/12/201518/02/201619/02/201621/03/2016280
30/07/2015InterimUSX9031/12/201431/12/201513/08/201514/08/201514/09/20150
05/02/2015FinalUSX19031/12/201331/12/201419/02/201520/02/201523/03/2015280
31/07/2014InterimUSX9031/12/201331/12/201413/08/201415/08/201415/09/20140
06/02/2014FinalUSX19031/12/201231/12/201319/02/201421/02/201424/03/2014280
01/08/2013InterimUSX9031/12/201231/12/201314/08/201316/08/201316/09/20130
31/01/2013FinalUSX19031/12/201131/12/201213/02/201315/02/201318/03/2013280
26/07/2012InterimUSX9031/12/201131/12/201208/08/201210/08/201210/09/20120
02/02/2012FinalUSX19531/12/201031/12/201115/02/201217/02/201219/03/2012280
28/07/2011InterimUSX8531/12/201031/12/201103/08/201105/08/201112/09/20110
27/01/2011FinalUSX18531/12/200931/12/201002/02/201104/02/201114/03/2011255
29/07/2010InterimUSX7031/12/200931/12/201002/08/201004/08/201013/09/20100
28/01/2010FinalUSX17131/12/200831/12/200903/02/201005/02/201015/03/2010230
30/07/2009InterimUSX5930/12/200830/06/200905/08/200907/08/200914/09/20090
29/01/2009FinalUSX15031/12/200731/12/200804/02/200906/02/200916/03/2009205
31/07/2008InterimUSX5530/12/200730/06/200808/08/200806/08/200815/09/20080
31/01/2008FinalUSX13531/12/200631/12/200706/02/200808/02/200817/03/2008187
26/07/2007InterimUSX5230/06/200630/06/200708/08/200710/08/200717/09/20070
01/02/2007FinalUSX12331/12/200531/12/200607/02/200709/02/200719/03/2007172
27/07/2006InterimUSX4930/12/200530/06/200609/08/200611/08/200618/09/20060
01/02/2006FinalUSX9231/12/200431/12/200508/02/200610/02/200620/03/2006130
29/07/2005InterimUSX3830/12/200430/06/200510/08/200512/08/200519/09/20050
27/01/2005FinalUSX64.531/12/200331/12/200409/02/200511/02/200521/03/200594
22/07/2004InterimUSX29.530/12/200330/06/200411/08/200413/08/200420/09/20040
29/01/2004FinalUSX5431/12/200231/12/200318/02/200420/02/200406/04/200479.5
24/07/2003InterimUSX25.530/12/200230/06/200320/08/200322/08/200306/10/20030
30/01/2003FinalUSX4731/12/200131/12/200219/02/200321/02/200307/04/200370
25/07/2002InterimUSX2330/12/200130/06/200221/08/200223/08/200207/10/20020
31/01/2002FinalUSX4731/12/200031/12/200120/02/200222/02/200208/04/200270
26/07/2001InterimUSX2330/12/200030/06/200122/08/200124/08/200105/10/20010
08/02/2001FinalUSX4731/12/199931/12/200021/02/200123/02/200109/04/200170
01/08/2000InterimUSX2330/12/199930/06/200004/09/200008/09/200023/10/20000
24/02/2000FinalUSX4731/12/199831/12/199906/03/200010/03/200017/04/200070
03/08/1999InterimUSX2330/12/199830/06/199906/09/199910/09/199925/10/19990

Top Dividend Posts

DateSubject
01/10/2019
08:30
arja: cheshire pets, sorry for delay in answering as I was abroad for a few days . It just means " no overhead resistance" when a share price breaks through to a higher level not seen previously . I notice AZN down in last day or so with disappointing announcement and share prices of drug companies can be volatile I guess as a lot of news flows . i am not sure if USA or UK is LEAD market for this stock .
14/8/2019
07:16
ayl30: RNS today looks positive. Should help share price trend continue
18/6/2019
13:01
bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth.
18/7/2018
12:01
bountyhunter: http://uk.advfn.com/stock-market/london/astrazeneca-AZN/share-news/AstraZeneca-Increases-Drug-Stockpile-in-Preparatio/77885692 that's one way to reduce any potential initial WTO tariffs/bottlenecks!
08/10/2017
12:51
cool druid: [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance | Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment
30/7/2017
19:12
nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend."
28/7/2017
15:10
minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh?
27/7/2017
10:46
minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675.
27/7/2017
10:10
steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend.
20/1/2017
17:26
philanderer: "Is Neil Woodford a fool to continue pumping money into Capita plc and AstraZeneca plc? 'Patience' AstraZeneca is Woodford's largest holding and an example of just how long he's prepared to be patient with a company he views as intrinsically undervalued. Earnings at the pharma group have suffered as a result of expiring patents on some of its top sellers and no improvement is expected to the bottom line until 2018. However, the company has maintained its dividend through this difficult period and offers a 5% yield at a current share price of around 4,400p. The dividend is forecast to start rising with the resumption of earnings growth in 2018 as a result of Astra's reinvigorated drugs pipeline. HTTP://money.aol.co.uk/2017/01/20/is-neil-woodford-a-fool-to-continue-pumping-money-into-capita-pl/
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 16:07:45